Abstract
An infectious particle, termed prion, composed largely and perhaps solely of a single protein, is the likely causative agent of prion disease. It produces lethal decline of cognitive and motor function. The responsible protein arrives at a pathogenic state by misfolding from a normal form that has ubiquitous tissue distribution. Prion diseases are often called spongiform encephalopathies.Probably most mammalian species develop these diseases. Specific examples in various animals are -Scrapie, Transmissible Mink Encephalopathy (TME ), Chronic Wasting Disease(CWD) and bovine spongiform encephalopathy (BSE). Humans are also susceptible to several prion diseases: Creutzfeld-Jacob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome (GSS), Fatal Familial Insomnia (FFI), Kuru and Alpers Syndrome. This paper reviews transmission of this diseases, protein involvement, nature of protein, the conversion process from PrPc to PrPSc, conversion of prion protein in vitro, the different proposed models for the conversion of PrPc to PrPSc, prion and other amyloid diseases, prion strains, structure of PrPc, the particular process that may induce prion disease, and immunization against these diseases.
Keywords: spongiform encephalopathies, gertsmann-sträussler-scheinker (gss), dementia, creutzfeldt-jakob disease (cjd), infectious, irradiation, prp protein, transgenic mouse, polymerization, amyloid diseases
Current Pharmaceutical Biotechnology
Title: Prion Disease: A Deadly Disease for Protein Misfolding
Volume: 6 Issue: 2
Author(s): Chiranjib Chakraborty, Shyam Nandi and Snehasis Jana
Affiliation:
Keywords: spongiform encephalopathies, gertsmann-sträussler-scheinker (gss), dementia, creutzfeldt-jakob disease (cjd), infectious, irradiation, prp protein, transgenic mouse, polymerization, amyloid diseases
Abstract: An infectious particle, termed prion, composed largely and perhaps solely of a single protein, is the likely causative agent of prion disease. It produces lethal decline of cognitive and motor function. The responsible protein arrives at a pathogenic state by misfolding from a normal form that has ubiquitous tissue distribution. Prion diseases are often called spongiform encephalopathies.Probably most mammalian species develop these diseases. Specific examples in various animals are -Scrapie, Transmissible Mink Encephalopathy (TME ), Chronic Wasting Disease(CWD) and bovine spongiform encephalopathy (BSE). Humans are also susceptible to several prion diseases: Creutzfeld-Jacob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome (GSS), Fatal Familial Insomnia (FFI), Kuru and Alpers Syndrome. This paper reviews transmission of this diseases, protein involvement, nature of protein, the conversion process from PrPc to PrPSc, conversion of prion protein in vitro, the different proposed models for the conversion of PrPc to PrPSc, prion and other amyloid diseases, prion strains, structure of PrPc, the particular process that may induce prion disease, and immunization against these diseases.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, Nandi Shyam and Jana Snehasis, Prion Disease: A Deadly Disease for Protein Misfolding, Current Pharmaceutical Biotechnology 2005; 6 (2) . https://dx.doi.org/10.2174/1389201053642321
DOI https://dx.doi.org/10.2174/1389201053642321 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Current Psychiatry Reviews Curcumin-glucoside, A Novel Synthetic Derivative of Curcumin, Inhibits α-Synuclein Oligomer Formation: Relevance to Parkinson's Disease
Current Pharmaceutical Design Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research Migraine and Obesity: Is There a Relationship? A Systematic Review and Meta-Analysis of Observational Studies
CNS & Neurological Disorders - Drug Targets Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders Emotion and Destination Memory in Alzheimer’s Disease
Current Alzheimer Research Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Gene Control of Synaptic Plasticity and Memory Formation: Implications for Diseases and Therapeutic Strategies
Current Molecular Medicine A Link Between Brain Insulin Resistance and Cognitive Dysfunctions: Targeting Ca2+/cAMP Signalling
Central Nervous System Agents in Medicinal Chemistry